scholarly journals High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus Infections

2006 ◽  
Vol 166 (19) ◽  
pp. 2138 ◽  
Author(s):  
Levita K. Hidayat ◽  
Donald I. Hsu ◽  
Ryan Quist ◽  
Kimberly A. Shriner ◽  
Annie Wong-Beringer
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
High Dose ◽  
Vancomycin Therapy ◽  
Methicillin Resistant

MRSA REMAINS A GREAT PRIORITY DUE TO THE TREMENDOUS MORTALITY --- A BIRD'S EYE VIEW

2021 ◽  
pp. 114-118
Author(s):  
Raghavendra Rao M. V ◽  
Mubasheer Ali ◽  
Yogendra Kumar Verma ◽  
Dilip Mathai ◽  
Tina Priscilla ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Drug Resistance ◽  
Chronic Infection ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Multiple Drug Resistance ◽  
Multiple Drug ◽  
High Dose ◽  
Benzyl Penicillin ◽  
Methicillin Resistant ◽  
Antimicrobial Sensitivity

Methicillin-resistant Staphylococcus aureus (MRSA) is difcult to treat with methicillin, amoxicillin, penicillin, oxacillin, and other commonly used antibiotics because of its resistance. Staphylococcus organisms rapidly develop drug resistance as many as 50% of the domiciliary and 80% of the hospital strains are now penicillin resistant. Staphylococcus aureus also show multiple drug resistance. Therefore, Staphylococcal isolates should always be tested for antimicrobial sensitivity and chronic infection should be treated by more than one drug. Before 1960,when methicillin, is the rst penicillin's-resistant penicillin's, was brought into use, about 1%of the strains of the Staphylococcus aureus were "methicillin resistant" and by 1970 in Britain their proportion has risen to about 5%.These strains are tolerant of, low therapeutic concentrations of methicillin, cloxacillin, benzyl penicillin and ampicillin.They do not destroy methicillin and cloxacillin, but most of them are penicillinase-producing as well as being "methicillin resistant" and therefore inactivate benzyl penicillin and ampicillin. Its resistance is uncertain since infections may be cured with a high dose of methicillin.

scholarly journals Ceftaroline Fosamil Use in 2 Pediatric Patients With Invasive Methicillin-Resistant Staphylococcus aureus Infections

2015 ◽  
Vol 20 (6) ◽  
pp. 476-480 ◽  
Author(s):  
Amanda W. Williams ◽  
Patrick M. Newman ◽  
Sara Ocheltree ◽  
Rachel Beaty ◽  
Ali Hassoun
Keyword(s):  
Staphylococcus Aureus ◽  
Septic Shock ◽  
Pediatric Patients ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Pediatric Intensive Care ◽  
Positive Outcome ◽  
Invasive Infection ◽  
Vancomycin Therapy ◽  
Ceftaroline Fosamil ◽  
Methicillin Resistant

Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is one of the most common pathogens causing pediatric infections including skin and soft tissue infections, pyogenic arthritis, osteomyelitis, and septic shock. For decades, patients were treated with antibiotics such as vancomycin and clindamycin, but there is an increasing incidence of resistance to these traditional therapies. We describe 2 cases of patients with CA-MRSA invasive infections with bacteremia who experienced vancomycin therapy failure but who were successfully treated with ceftaroline fosamil. Case 1 involves an 8-year-old Hispanic male who was diagnosed with CA-MRSA bacteremia, thigh abscess, and osteomyelitis. The patient was admitted to the pediatric intensive care unit in septic shock. Case 2 involves an 8-year-old Caucasian male who was diagnosed with CA-MRSA sepsis, right arm abscess, and osteomyelitis. We were able to successfully treat both patients with CA-MRSA sepsis and invasive infection—who failed vancomycin therapy—with ceftaroline fosamil with no adverse efiects. Despite the positive outcome in both pediatric patients, clinical trials with ceftaroline fosamil are needed to further support its use in pediatric patients.

Adaptation of Methicillin-Resistant Staphylococcus aureus in the Face of Vancomycin Therapy

2006 ◽  
Vol 42 (Supplement_1) ◽  
pp. S40-S50 ◽  
Author(s):  
George Sakoulas ◽  
Robert C. Moellering ◽  
George M. Eliopoulos
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Vancomycin Therapy ◽  
Methicillin Resistant ◽  
The Face

Clinical Outcomes of Linezolid vs Vancomycin in Methicillin-Resistant Staphylococcus aureus Ventilator-Associated Pneumonia

2011 ◽  
Vol 26 (6) ◽  
pp. 385-391 ◽  
Author(s):  
Jeannie D. Chan ◽  
Tam N. Pham ◽  
Jenny Wong ◽  
Michelle Hessel ◽  
Joseph Cuschieri ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Clinical Cure ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Signs And Symptoms ◽  
Ventilator Associated Pneumonia ◽  
Vancomycin Therapy ◽  
Methicillin Resistant ◽  
Treatment Standard ◽  
Primary Endpoints ◽  
Days Of Therapy

Background: Vancomycin has been the treatment standard for methicillin-resistant Staphylococcus aureus (MRSA) infections, but clinical efficacy is limited. We report outcomes of a cohort with MRSA ventilator-associated pneumonia (VAP) treated with vancomycin vs linezolid. Methods: Retrospective analysis of 113 participants with MRSA VAP confirmed by bronchoscopy who have been initiated on therapy with either vancomycin or linezolid within 24 hours after bronchoscopy and completed ≥7 days of therapy during their hospitalization from July 2003 to June 2007. The primary endpoints were hospital survival and clinical cure, defined as resolution of signs and symptoms of VAP or microbiological eradication after completion of therapy along with clinical pulmonary infection score (CPIS) ≤6 at day 7 of therapy. Results: At hospital discharge, 23/27 (85.2%) of linezolid and 72/86 (83.7%) of vancomycin recipients had survived ( P = .672). In comparison to linezolid recipients, the adjusted odds ratio (OR) for survival was 0.72 (95% confidence interval [CI]: 0.16-3.27) with vancomycin therapy. Clinical cure was achieved in 24/27 (88.9%) of linezolid and 63/86 (73.3%) of vancomycin recipients ( P = .066). Compared to linezolid recipients, the adjusted OR for clinical cure was 0.24 (95% CI: 0.05-1.10) with vancomycin therapy. Survival and clinical cure did not differ significantly between vancomycin recipients with trough level ≥15 and <15 μg/mL, respectively. Conclusions: Our results suggested no survival benefit but a trend toward higher cure rate with linezolid therapy. The optimal treatment of MRSA VAP requires further study through randomized, controlled trials.

scholarly journals Comparison of Levofloxacin, Alatrofloxacin, and Vancomycin for Prophylaxis and Treatment of Experimental Foreign-Body-Associated Infection by Methicillin-Resistant Staphylococcus aureus

2002 ◽  
Vol 46 (5) ◽  
pp. 1503-1509 ◽  
Author(s):  
Pierre Vaudaux ◽  
Patrice Francois ◽  
Carmelo Bisognano ◽  
Jacques Schrenzel ◽  
Daniel P. Lew
Keyword(s):  
Staphylococcus Aureus ◽  
Foreign Body ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Experimental Models ◽  
High Dose ◽  
Methicillin Resistant ◽  
Infectious Dose ◽  
Prevention Of Infections ◽  
Guinea Pig Model ◽  
Therapeutic Activities

ABSTRACT The prophylactic and therapeutic activities of two fluoroquinolones, levofloxacin and alatrofloxacin (the l-Ala-l-Ala prodrug of trovafloxacin), were compared to those of vancomycin in two different experimental models of foreign-body-associated infections caused by methicillin-resistant but quinolone-susceptible Staphylococcus aureus (MRSA) isolates. In a guinea pig model of prophylaxis, subcutaneously implanted tissue cages were infected with 103 CFU of MRSA, which was a 100% infectious dose in control animals. A single dose of 50 mg of levofloxacin per kg of body weight, administered intraperitoneally 3 h before bacterial challenge, was more efficient than vancomycin for the prevention of infections in tissue cages with MRSA inocula of 104 and 105 CFU. In a rat model used to evaluate therapy of chronic tissue cage infection caused by MRSA, the efficacies of 7-day high-dose regimens of levofloxacin (100 mg/kg once a day [q.d.] or 50 mg/kg twice a day [b.i.d.]) or alatrofloxacin (50 mg/kg q.d.) were compared to the efficacy of vancomycin (50 mg/kg b.i.d.). Active levels of levofloxacin, trovafloxacin, and vancomycin were continuously present in tissue cage fluid, with the levels exceeding the minimal bactericidal concentrations for MRSA during therapy. The q.d. and b.i.d. regimens of levofloxacin had equivalent activities and were significantly (P < 0.05) more active than alatrofloxacin or vancomycin in decreasing the viable counts of MRSA in tissue cage fluids. No quinolone-resistant mutants emerged during therapy with either fluoroquinolone. The mechanisms explaining the inferior activity of alatrofloxacin compared to the activity of levofloxacin against chronic foreign-body-associated infections by MRSA are unknown.

scholarly journals Reduced susceptibility to daptomycin in methicillin-resistant Staphylococcus aureus isolated from catheter-related bloodstream infections

2021 ◽  
Author(s):  
Sho Ohyatsu ◽  
Tomoyuki Nariyama ◽  
Kotaro Matsumoto ◽  
Yuki Moritoki ◽  
Kentaro Kikuchi
Keyword(s):  
Staphylococcus Aureus ◽  
Blood Culture ◽  
Drug Treatment ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Bloodstream Infections ◽  
High Dose ◽  
Methicillin Resistant ◽  
Treatment Methods ◽  
History Of ◽  
The Mean

Abstract Background The appearance of reduced susceptibility to daptomycin in methicillin-resistant Staphylococcus aureus (MRSA) has recently been reported. It is unclear how likely MRSA involved in catheter-related bloodstream infections (CRBSI) is to dampen susceptibility to daptomycin. We investigated the minimum inhibitory concentrations (MIC) of daptomycin in MRSA isolated from the blood of patients with CRBSI and examined how it was affected by previous anti-MRSA drug treatment. Methods A total of 115 patients whose blood culture samples were found to contain MRSA were enrolled in this study. The MIC of daptomycin and vancomycin and whether the subjects had a history of anti-MRSA drug treatment were investigated and compared between the CRBSI and non-CRBSI groups. Results The mean MIC of daptomycin was significantly higher for the 46 CRBSI-related MRSA isolates than for the 69 non-CRBSI-related MRSA isolates (0.78 vs. 0.33, respectively; p<0.0001). Among the CRBSI-related MRSA isolates, those collected from patients with a history of anti-MRSA drug treatment had significantly higher MIC (1.27 vs. 0.53, respectively; p <0.01). During treatment, MRSA was detected again in 10 CRBSI and 4 non-CRBSI patients, and all of the CRBSI-related MRSA isolates exhibited 1-2 log2 increases in their daptomycin MIC. Conclusions It is considered that when MRSA in catheter biofilms is exposed to anti-MRSA drugs, strains with reduced susceptibility to daptomycin are able to survive and disperse into the blood. Catheters should be removed if an MRSA-induced CRBSI is suspected. Further study of whether high-dose daptomycin treatment is effective when catheters cannot be immediately removed is needed.

Sign in / Sign up

Export Citation Format

Share Document